Why this chain matters

Regeneron Pharmaceuticals, Inc. (REGN) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when REGN performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to REGN's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • SANOFI (SANOFI) - confidence 90%.
  • Alnylam Pharmaceuticals, Inc. (ALNY) - confidence 85%.
  • Genelux Corporation (GNLX) - confidence 72%.
  • Legend Biotech Corporation (LEGN) - confidence 72%.
  • Lantheus Holdings, Inc. (LNTH) - confidence 72%.
  • IRIDEX Corporation (IRIX) - confidence 72%.
  • Telix Pharmaceuticals Limited (TLX) - confidence 72%.
  • MacroGenics, Inc. (MGNX) - confidence 72%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • MAIA Biotechnology, Inc. (MAIA) - confidence 92%.
  • DISTRIBUTOR-CUSTOMERS (DISTRIBUTOR-CUSTOMERS) - confidence 92%.
  • Merck & Co., Inc. (MRK) - confidence 72%.
  • Sanofi (SNYNF) - confidence 72%.
  • Arcus Biosciences, Inc. (RCUS) - confidence 72%.
  • McKesson Corporation (MCK) - confidence 72%.
  • Legend Biotech Corporation (LEGN) - confidence 72%.
  • Keros Therapeutics, Inc. (KROS) - confidence 72%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • Regeneron Pharmaceuticals, Inc.: Reciprocal relationship from MAIA graph: In February 2021, the Company entered into a Drug Supply Agreement (the “Drug Supply Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”) to perform one clinical trial for the treatment of patients with Non-Sm
  • Regeneron Pharmaceuticals, Inc.: We sell our marketed products for which we record net product sales in the United States to several distributors and specialty pharmacies, as applicable (collectively, "distributor customers"), which generally sell the product directly to healthcare providers
  • SANOFI: The Company is party to a global, strategic collaboration with Sanofi to research, develop, and commercialize fully human monoclonal antibodies, which currently consists of Dupixent ® (dupilumab), Kevzara ® (sarilumab), and itepekimab . Sanofi is generally res
  • REGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC: 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 1403 tracked holders.
  • Alnylam Pharmaceuticals, Inc.: Reciprocal relationship from ALNY graph: bal, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targets expressed in the

Who benefits and who is exposed

If Regeneron Pharmaceuticals, Inc. outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If REGN struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

How to read the signal

A compact graph can still be useful when the named counterparties are specific and the evidence is direct. Investors should read each relationship as a working hypothesis about exposure, then compare it with revenue mix, segment performance, margin pressure, and management commentary in the next filing cycle.

The strongest signals usually have three traits: a named counterparty, a clear commercial role, and repeated language over time. A one-off mention is weaker. A relationship tied to manufacturing, purchasing, licensing, distribution, or customer concentration is stronger because it can affect revenue durability, operating leverage, or execution risk.

For Regeneron Pharmaceuticals, Inc., the current graph gives analysts a starting map rather than a final conclusion. The supplier side points to operating dependencies. The customer side points to demand dependencies. The evidence trail shows which edges deserve deeper work before they are used in a trade or portfolio risk review.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.